Vitamin B12 Compound Crosses Blood-Brain Barrier to Target Deadly Brain Tumors
A modified B12 molecule delivers nitric oxide directly to glioblastoma tumors and boosts existing treatments in animal and lab studies.
Summary
Researchers have developed a vitamin B12-based compound called nitrosylcobalamin that can cross the blood-brain barrier and accumulate preferentially in glioblastoma tumors. Glioblastoma is one of the most lethal brain cancers, with most patients surviving less than 15 months after diagnosis. The compound releases nitric oxide directly into tumor tissue, where it remains active for at least 24 hours — far longer than in healthy surrounding tissue. When combined with standard glioblastoma treatments like temozolomide and TRAIL therapy, the compound dramatically increased tumor cell suppression in lab studies. While results are early-stage and limited to animal and cell studies, the research offers a potentially significant new strategy for a cancer that has resisted most treatment advances for decades.
Detailed Summary
Glioblastoma multiforme is one of medicine's most stubborn problems. Even with aggressive surgery, radiation, and chemotherapy, median survival remains under 15 months. A central challenge is the blood-brain barrier, which blocks most drugs from reaching brain tumors at therapeutic concentrations. A newly published study in Oncoscience suggests a creative molecular workaround may be within reach.
Researchers at Nitric Oxide Services, LLC and the Cleveland Clinic Foundation developed nitrosylcobalamin (NO-Cbl), a modified form of vitamin B12 engineered to carry and release nitric oxide. Vitamin B12 naturally crosses the blood-brain barrier through specialized transport mechanisms, making it an attractive molecular vehicle. After systemic administration in rat glioblastoma models, NO-Cbl successfully crossed the barrier and preferentially accumulated in tumor tissue rather than healthy brain or peripheral organs.
The compound's tumor retention was notably sustained. Nitrate levels — a marker of nitric oxide delivery — remained elevated in glioblastoma tissue for at least 24 hours post-treatment, while declining rapidly in normal tissues. This selective, prolonged activity suggests NO-Cbl could deliver a continuous therapeutic payload to tumors while sparing healthy tissue from excess nitric oxide exposure.
Particularly promising were the combination therapy results. In human glioblastoma cell lines (U87 and D54), pairing NO-Cbl with either temozolomide or TRAIL produced synergistic tumor suppression — meaning the combined effect substantially exceeded what each treatment achieved individually. This raises the prospect of meaningfully enhancing standard-of-care regimens without simply adding toxicity.
Important caveats apply. This is a pilot study conducted in animals and cell cultures, with no human trial data yet. The jump from rodent pharmacokinetics to human clinical response is substantial. Nonetheless, the mechanistic rationale is sound, and the findings justify advancing NO-Cbl into more rigorous preclinical and, eventually, clinical evaluation.
Key Findings
- Nitrosylcobalamin (NO-Cbl) crossed the blood-brain barrier and preferentially accumulated in glioblastoma tumor tissue in rat models.
- Nitric oxide delivery to tumor tissue remained elevated for at least 24 hours, while healthy tissue levels dropped quickly.
- Combining NO-Cbl with temozolomide or TRAIL therapy produced synergistic tumor suppression in human glioblastoma cell lines.
- NO-Cbl showed antitumor activity across a broad range of cancer types in the NCI-60 human tumor cell line panel.
- Vitamin B12's natural blood-brain barrier transport mechanism makes it a viable drug-delivery vehicle for brain cancer therapies.
Methodology
This is a research summary based on a pilot study published in the peer-reviewed journal Oncoscience. Evidence comes from NCI-60 cell line screening, rat pharmacokinetic studies, and human glioblastoma cell line combination experiments. The lead author is affiliated with both a private biotech entity and the Cleveland Clinic, which warrants awareness of potential conflicts of interest.
Study Limitations
All data are from animal models and cell cultures; human pharmacokinetics and safety profiles are entirely unknown. The study is a pilot with a small evidence base, and the lead author's affiliation with a nitric oxide-focused company introduces potential bias. Independent replication and peer scrutiny of raw data are needed before drawing firm conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: